Ticker LaunchUplisting · GTBP
GT Biopharma, Inc.
Formerly GT Biopharma, Inc.; OXIS INTERNATIONAL INC
GT Biopharma, Inc. (GTBP), already reporting to the SEC, moved up to Nasdaq Capital Market on Feb 12, 2021 with an offering at $5.50 per share raising $23.6M. Roth Capital was lead-left underwriter, joined by Dawson James. Baker McKenzie advised the company and Schiff Hardin advised the underwriters.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immuno-therapeutics built on its TriKE and TetraKE platforms, which are designed to engage a patient's natural killer cells against cancer or virus-infected cells. Its first clinical indication is relapsed or refractory acute myelogenous leukemia.
- Status
- Uplisting
- Ticker
- GTBP
- Exchange
- Nasdaq Capital Market
- Listed
- Feb 12, 2021
- Price
- $5.50
- Raised
- $23.6M
- Market cap at IPO price
- $113.5M
- First filed
- Aug 24, 2016
- Underwriters
- Roth Capital and Dawson James
- Company counsel
- Baker McKenzie
- Underwriters' counsel
- Schiff Hardin
- Sector
- Biotech & pharma
- Country / state
- CA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Aug 24, 2016
- Latest amendment Feb 9, 2021
- Final prospectus (424B4) Feb 12, 2021
- All filings on EDGAR CIK 109657
Other Biotech & pharma uplistings in 2021
- Evotec SEEVO · Nov 5, 2021 · $435M
- Zivo Bioscience, Inc.ZIVO · Jun 1, 2021 · $13.8M
- Nexentis Technologies Inc.SVFD · May 17, 2021 · $12M
- Protagenic Therapeutics, Inc.\newPTIX · Apr 28, 2021 · $13.2M
- Lexaria Bioscience Corp.LEXX · Jan 14, 2021 · $9.6M
- Zevra Therapeutics, Inc.KMPH · Jan 11, 2021